The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Next-generation sequencing of cell-free circulating solid tumor DNA addresses two
challenges in contemporary cancer care. First this method of massively parallel and deep …

Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …

Non-small cell lung cancer (NSCLC) is one of the major causes of cancer-related mortality
globally. Despite the availability of therapeutic options, the improvement in patient survival is …

Non-small cell lung cancer (NSCLC) is reported to have a high incidence rate and is one of
the most prevalent types of cancer contributing towards 85% of all incidences of lung cancer …

In the last decades the approach to cancer patient management has been deeply
revolutionized. We are moving from a “one-fits-all” strategy to the “personalized medicine” …

Abstract The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …

Acquired resistance remains a major barrier for the treatment of non-small cell lung cancer,
while cancer stem cells (CSCs) usually lead to the occurrence of drug resistance. We herein …

The aim of this study was to explore the role of long non-coding RNA UCA1 (urothelial
cancer-associated 1) in acquired resistance to epidermal growth factor receptor tyrosine …